GHRP-2 (Pralmorelin)

Introduction

GHRP-2 (pralmorelin) is a synthetic hexapeptide growth-hormone-releasing peptide developed in the 1990s. Member of the broader GH-secretagogue class. Used as a diagnostic GH-stimulation agent in some countries; not approved as a therapeutic in the United States.

Mechanism of Action

Agonist at the growth-hormone-secretagogue receptor (GHS-R1a), the endogenous receptor for ghrelin. Receptor activation drives pulsatile GH release from somatotrophs and synergizes with endogenous GHRH. Co-administration with a GHRH or GHRH-analogue (e.g., sermorelin, CJC-1295) produces additive GH release in research protocols.

Research Indications

GH-deficiency diagnostics, adult sarcopenia, cachexia adjunct, and recovery-oriented protocols. Not a substitute for recombinant human GH where indicated.

Reconstitution

Typical 5 mg lyophilized vial: add 2 mL of bacteriostatic water, swirl gently. Final concentration 2500 mcg/mL (2.5 mg/mL) — each 0.04 mL (4 units on a U-100 insulin syringe) delivers 100 mcg.

Dosing Protocol (research literature)

Research protocols typically dose 100–300 mcg subcutaneously 1–3 times daily, with the largest pulse pre-sleep to align with endogenous GH rhythm. Frequent pairing: GHRP-2 + sermorelin or CJC-1295 (no DAC), each at 100 mcg, pre-sleep on empty stomach. Cycle length 8–12 weeks with 4-week off before re-cycling.

Administration

Subcutaneous into abdominal fat, rotating sites. Dose on an empty stomach (food blunts the GH pulse). Pre-sleep dose 60–90 minutes after last food/drink other than water.

Storage & Handling

Lyophilized: refrigerate (2–8°C). Reconstituted: refrigerate; stable approximately 21–28 days. Protect from light.

Side Effects

Transient: flushing, mild injection-site reaction, hunger (less pronounced than GHRP-6). Documented modest transient elevations in cortisol and prolactin.

Contraindications

Active malignancy, untreated proliferative diabetic retinopathy, pregnancy, lactation, uncontrolled diabetes.

Monitoring

Baseline IGF-1, fasting glucose, HbA1c, lipid panel. Re-measure IGF-1 at 6–8 weeks; trough IGF-1 above the age-adjusted reference range warrants dose reduction. Counsel on carpal-tunnel symptoms, peripheral edema, and arthralgia at higher exposures.

Disclaimer

This article is for informational and research-reference purposes only. Nothing in this document constitutes medical advice, a prescription, or a recommendation from a physician. The reconstitution, dosing, and protocol information above reflects ranges commonly cited in published research and clinician-directed protocols — it is provided as reference material only, not as instructions, an endorsement of off-label use, or a substitute for individualized medical evaluation.

Customers should do their own research and consult their own physician before considering any peptide protocol. Whether a given compound is appropriate for an individual — and at what dose, for what duration, and alongside what monitoring — is a decision that only a licensed clinician with knowledge of that individual's medical history, current medications, and conditions can make.

The platform and the author make no claim that any compound described here is safe, effective, or appropriate for any particular person or purpose, and accept no responsibility for outcomes arising from self-directed use of the information.